Figure 5. OMTX703 strongly reduces tumor growth in ES8 xenograft models.
(A) Therapeutic effect of OMTX003 and OMTX703 in ES8 Ewing sarcoma xenografts. Immunocompromised NOD-SCID-IL-2Rgnull/null mice (NSG) were injected with 1·106 ES8 cells at their flank. Treatment with OMTX003 (n = 8), OMTX703 (n = 8 for each dosing group) or control vehicle (n = 7) was started when tumor volumes reached of about 100 mm3. The curves show individual tumor volumes for a period of 30-days drug exposure. (B) The panel shows Kaplan-Meier curves. The p < 0.019 value for differences between the treated OMTX703 (60 mg/kg) and control mice were performed with the log-rank (Mantel-Cox) test. (C) The curves show the smoothed grouped median relative tumor volumes. The OMTX703 (60 mg/kg) treatment show a significant blockade of ES8 tumor growth as compared to control group of mice using unpaired t-test and two-tailed p-value (p < 0.0001). However, no significant effect of low doses OMTX (10 or 30 mg/kg) on this tumor growth. (D) RPPA profiling (GSE#114866) of control (n=7), OMTX003 (10 mg/kg; n = 8), OMTX703 (10 mg/kg; n = 8), OMTX703 (30 mg/kg; n = 8) and OMTX703 (60 mg/kg; n = 8)-treated ES8 xenografts following a 2-week exposure identifies statistically significant 60 proteins at a false discovery rate (FDR) of 0.01.